EBR Systems (ASX:EBR) Advances Leadless Pacemaker Technology with Successful Trials
EBR Systems (ASX:EBR) reports successful SOLVE-CRT trials and outlines a clear FDA approval pathway for its innovative leadless pacemaker system.
Category: Healthcare
4DMedical Limited (ASX:4DX) Completes Oversubscribed $8.4m SPP
4DMedical Limited (ASX:4DX) completes an oversubscribed $8.4m SPP, raising $13.9m to advance lung diagnostic technologies.
Immutep Limited (ASX:IMM) Initiates Phase III Trial for Non-Small Cell Lung Cancer
Immutep Limited (ASX:IMM) initiates pivotal Phase III trial for non-small cell lung cancer, aiming to establish new treatment standards.
Telix Pharmaceuticals Limited (ASX:TLX) Receives FDA Approval for Gozellix®
Telix Pharmaceuticals (ASX:TLX) announces FDA approval for Gozellix®, expanding prostate cancer imaging access in the U.S.
Rhythm Biosciences Ltd (ASX:RHY) Records First Commercial Sales of geneType Products
Rhythm Biosciences (ASX:RHY) records its first commercial sales of geneType products, anticipating growth throughout the year.
Imugene Limited (ASX:IMU) Granted FDA Fast Track Designation for Azer-cel
Imugene Limited (ASX:IMU) secures FDA Fast Track designation for its allogeneic CAR T-cell therapy azer-cel, advancing treatment for relapsed or refractory diffuse large B-cell lymphoma.
Adherium Limited (ASX:ADR) Raises $2.6M through Convertible Notes
Adherium Limited (ASX:ADR) raises $2.6M through convertible notes to expand its Hailie® Smartinhaler® platform in the US.
Orthocell Limited (ASX:OCC) Receives Singapore Regulatory Approval for Striate+
Orthocell Limited (ASX:OCC) secures Singapore’s regulatory approval for Striate+, boosting its global market expansion and sales growth.
Syntara Limited (ASX:SNT) Expands Skin Scarring Program with SNT-9465
Syntara Limited (ASX:SNT) expands its skin scarring program with the new SNT-9465 drug, initiating Phase 1a/b trials in 2025.
Chimeric Therapeutics Limited (ASX:CHM) Announces $3.2 Million Entitlement Offer
Chimeric Therapeutics Limited (ASX:CHM) announces a $3.2 million entitlement offer to fund its ongoing cell therapy clinical trials.